Get The Best Care for Your Chronic Lymphocytic Leukemia (CLL)
The CLL Society Inc. is a patient–centric, physician–curated nonprofit organization focused on
patient education, support, and research. Dedicated to addressing the unmet needs of the Chronic Lymphocytic Leukemia (CLL) community,
our goal is to provide real, recent and relevant information and to be the “go to place” for CLL patients and caregivers.
What’s New in CLL?
- There are many powerful combinations of drugs with and without chemotherapy being studied in CLL that offer the promise of being able to stop there with no detectable cancer. At ASH 2018, Dr. Koffman interviewed Dr. Lamanna for her overview of all this research.
- FDA approval of the combination of venetoclax and obinutuzumab for treatment naïve CLL patients marks the first fixed duration non-chemotherapy options. The deep responses and clinically significant advantage in terms of progression free and overall survival are hopeful indicators that this will be a serious alternative frontline and perhaps the first of many innovative non-chemo combinations.
- If ibrutinib is good at stopping CLL from growing and venetoclax is good at killing CLL cells, then Prof Hillmen asks the question: What happens when we combine them? He shares the exciting results of the CLARITY trial in Dr. Koffman’s ASH 2018 interview here.
CLL Society Expert Access™
Access to a CLL expert is critical to ensure receiving the best possible care and has proven to improve survival. In partnership with Verastem Oncology and InfiniteMD, the CLL Society is proud to offer this free second opinion program for CLL patients.
We Are in this Together
-
Pingback: ABT-199 (venetoclax) in Combination Treatment for CLL